Firstline - Clinical Decisions

Notes

This model predicts the risk of resistance to antipseudomonal beta-lactams among respiratory and bloodstream isolates of Pseudomonas aeruginosa and other non-fermenting gram-negative bacilli (NFGN) such as Acinetobacter baumanii, etc.

It is particularly useful in critically-ill patients with risk of infections due to P. aeruginosa or NFGN in the respiratory tract (VAP) or bloodstream (prolonged hospitalization or severely immunecompromised hosts with qSOFA score ≥2)

Select All Applicable Risk Factors

Bronchiectasis/cystic fibrosis

Prior infections or colonization with beta-lactam resistant P. aeruginosa within past 12 months

Prior use of antipseudomonal beta-lactams for >48 hours within 3-30 days of index infection

Antipseudomonal beta-lactams include piperacillin-tazobactam, ceftazidime, cefepime, meropenem, and imipenem
Resistance to any of these agents confers beta-lactam resistant P. aeruginosa

More Information

References

Al-Jaghbeer MJ, et al. Infection 2018; 46: 487-94. doi: 10.1007/s15010-018-1147-z
Foster RA, et al. Antibiotics (Basel) 2019; 8: e15. doi:10.3390/antibiotics8010015

Attribution

Guideline adapted from Prisma Health-MIdlands

Preview

Beta-lactam Resistant P. aeruginosa Prediction Score

Notes

Select All Applicable Risk Factors

More Information